title: Recombinant allergens for specific immunotherapy.
abstract: Recombinant DNA technology provides the means for producing allergens that are equivalent to their natural counterparts and also genetically engineered variants with reduced IgE-binding activity. The proteins are produced as chemically defined molecules with consistent structural and immunologic properties. Several hundred allergens have been cloned and expressed as recombinant proteins, and these provide the means for making a very detailed diagnosis of a patient's sensitization profile. Clinical development programs are now in progress to assess the suitability of recombinant allergens for both subcutaneous and sublingual immunotherapy. Recombinant hypoallergenic variants, which are developed with the aim of increasing the doses that can be administered while at the same time reducing the risks for therapy-associated side effects, are also in clinical trials for subcutaneous immunotherapy. Grass and birch pollen preparations have been shown to be clinically effective, and studies with various other allergens are in progress. Personalized or patient-tailored immunotherapy is still a very distant prospect, but the first recombinant products based on single allergens or defined mixtures could reach the market within the next 5 years.
authors.affiliation: Research and Development Division, Allergopharma Joachim Ganzer KG, Reinbek, Germany. oliver.cromwell@allergopharma.de
authors.forename: Oliver
authors.initials: O
authors.lastname: Cromwell
authors.forename: Dietrich
authors.initials: D
authors.lastname: Häfner
authors.forename: Andreas
authors.initials: A
authors.lastname: Nandy
mesh_terms: D000485:Allergens / Q000276:immunology / Q000627:therapeutic use*; D003888:Desensitization, Immunologic / Q000379:methods*; D006801:Humans; D057285:Precision Medicine / Q000379:methods*; D011994:Recombinant Proteins / Q000276:immunology / Q000627:therapeutic use*
chemical_list: D000485:Allergens; D011994:Recombinant Proteins